Table 2.
Clinico-pathological features of both cohorts
| Patient/tumor characteristics | QUASAR | DACHS |
|---|---|---|
| Origin | United Kingdom | Germany |
| Number of patients | 2,190 | 2,448 |
| WSI format | SVS | SVS |
| MSI/dMMR ground truth | IHC 4-plex or IHC 2-plex | PCR 3-plex |
| MSI/dMMR, n (%) | 246 (11%) | 210 (9%) |
| MSS/pMMR, n (%) | 1,529 (70%) | 1,836 (75%) |
| Mean age at diagnosis (standard deviation) | 62.20 (9.60) | 68.46 (10.82) |
| Colon cancer, n (%) | 1,474 (67%) | 1,488 (61%) |
| Rectal cancer, n (%) | 526 (24%) | 960 (39%) |
| Organ unknown, n (%) | 190 (9%) | 0 (0%) |
| Female, n (%) | 848 (39%) | 1,012 (41%) |
| Male, n (%) | 1,334 (61%) | 1,436 (59%) |
| Gender unknown (%) | 8 (0%) | 0 (0%) |
| UICC stage I, n (%) | 1 (0%) | 485 (20%) |
| UICC stage II, n (%) | 1,988 (91%) | 801 (33%) |
| UICC stage III, n (%) | 192 (9%) | 822 (34%) |
| UICC stage IV, n (%) | 0 (0%) | 337 (14%) |
| UICC stage unknown (%) | 9 (0%) | 3 (0%) |
| BRAF mutation, n (%) | 120 (5%) | 151 (6%) |
| BRAF wild type, n (%) | 1,358 (62%) | 1,930 (79%) |
| BRAF status unknown (%) | 712 (33%) | 367 (15%) |
| KRAS mutation, n (%) | 555 (25%) | 667 (27%) |
| KRAS wild type, n (%) | 882 (40%) | 1,397 (57%) |
| KRAS status unknown (%) | 753 (35%) | 374 (15%) |
| NRAS mutation, n (%) | 41 (2%) | n.a. |
| NRAS wild type, n (%) | 1,430 (65%) | n.a. |
| NRAS status unknown (%) | 719 (33%) | n.a. |
| PIK3CA mutation, n (%) | 72 (3%) | n.a. |
| PIK3CA wild type, n (%) | 1,343 (61%) | n.a. |
| PIK3CA status unknown (%) | 775 (36%) | n.a. |
| Right-sided tumor, n (%) | 754 (34%) | 819 (33%) |
| Left-sided tumor, n (%) | 1,158 (53%) | 1,607 (66%) |
| Sidedness unknown, n (%) | 150 (13%) | 22 (1%) |
| Etiology | not specified | any |
Details on missing image and/or biomarker data for patients in the QUASAR and DACHS cohort can be found in Figures S1 and S2, respectively.